| Price | 1,894.00p on 23-10-2026 at 18:15:10 |
|---|---|
| Change | -20.00p -1.04% |
| Buy | 1,893.50p |
| Sell | 1,892.00p |
| Last Trade: | Unknown 406.00 at 1,894.00p |
| Day's Volume: | 5,516,426 |
| Last Close: | 1,894.00p |
| Open: | 1,911.50p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,881.00p - 1,911.50p |
| 52wk Range: | 1,624.50p - 2,282.00p |
| Market Capitalisation: | £75.89b |
| VWAP: | 1,893.69008p |
| Shares in Issue: | 4.01b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 406 | 1,894.00p | OTC Trade |
16:56:47 - 23-Oct-26 |
| Sell* | 129,276 | 1,890.49474p | Negotiated Trade |
16:35:27 - 23-Oct-26 |
| Sell* | 5 | 1,894.00p | Automatic Execution |
16:35:13 - 23-Oct-26 |
| Sell* | 2,936,415 | 1,894.00p | Uncrossing Trade |
16:35:13 - 23-Oct-26 |
| Sell* | 483 | 1,892.50p | Automatic Execution |
16:29:59 - 23-Oct-26 |
| Buy* | 124 | 1,893.00p | Automatic Execution |
16:29:59 - 23-Oct-26 |
| Buy* | 400 | 1,893.00p | Automatic Execution |
16:29:59 - 23-Oct-26 |
| Buy* | 293 | 1,893.00p | Automatic Execution |
16:29:59 - 23-Oct-26 |
| Buy* | 520 | 1,893.00p | Automatic Execution |
16:29:59 - 23-Oct-26 |
| Buy* | 480 | 1,892.50p | Automatic Execution |
16:29:59 - 23-Oct-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 21st Oct 2026 7:00 am | RNS | US FDA approves Hibsago for chronic hepatitis B |
| 19th Oct 2026 5:21 pm | RNS | Jemperli approved in MSI-H/dMMR rectal cancer |
| 19th Oct 2026 7:00 am | RNS | Ris-Rez positive early data in lung cancer |
| 15th Oct 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 14th Oct 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 13th Oct 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 12th Oct 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 8th Oct 2026 3:00 pm | RNS | Wendy Becker CBE - New Directorship |
| 6th Oct 2026 3:00 pm | RNS | Admission to Trading |
| 1st Oct 2026 3:00 pm | RNS | Total Voting Rights |
